A lateral nasal implant is an alternative treatment for patients experiencing chronic sinus infections.
Propel is the first (and only) product on the market that targets the inflamed sinus tissues directly, opening them up for improved drainage and a reduction in symptoms.
The implant, inserted during an endoscopic sinus procedure, resembles a spring and delivers a measured dose of mometasone furoate, an anti-inflammatory steroid that gradually dissolves. It is completely absorbed by the body 4-6 weeks after implantation. Approved by the FDA in 2013, Propel is safe and effective, and carries fewer risks of post-surgical scarring or inflammation. Patients typically have a smaller chance of requiring follow-up surgery.